Viral hemorrhagic fever
MONDO:0018087A viral infectious disease caused by RNA viruses in the Arenaviridae, Bunyaviridae, Filoviridae, or Flaviviridae family, and characterized by a severe multisystem syndrome, with damage to the vascular system and hemorrhaging.
Also known as: haemorrhagic fever, hemorrhagic fever, hemorrhagic fevers, VHF, VHFs, haemorrhagic fevers, viral, viral haemorrhagic fever
54 clinical trials for this condition and its sub-types, 10 tagged with Viral hemorrhagic fever itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Viral hemorrhagic fever
-
Ebola hemorrhagic fever 21 trials
-
Dengue hemorrhagic fever 7 trials
1 sub-type
- Dengue shock syndrome 6 trials
-
Arenavirus hemorrhagic fever 0 trials · 6 incl. sub-types
2 sub-types
- Lassa fever 6 trials
- Argentine hemorrhagic fever 0 trials
-
Crimean-Congo hemorrhagic fever 5 trials
-
Marburg hemorrhagic fever 4 trials
-
Rift valley fever 3 trials
-
Hantavirus pulmonary syndrome 2 trials
-
Venezuelan equine encephalitis 1 trial
-
Hemorrhagic fever-renal syndrome 1 trial
-
Bolivian hemorrhagic fever 0 trials
-
Brazilian hemorrhagic fever 0 trials
-
Chapare hemorrhagic fever 0 trials
-
Kyasanur forest disease 0 trials
1 sub-type
- Alkhurma hemorrhagic fever 0 trials
-
Lujo hemorrhagic fever 0 trials
-
Omsk hemorrhagic fever 0 trials
-
Venezuelan hemorrhagic fever 0 trials
-
Ebola vaccine in a nasal spray? early trial halted
Vaccine Stopped earlyThis early-stage trial tested a nasal spray vaccine against Ebola in 15 healthy adults. The vaccine uses a weakened common cold virus to deliver a piece of the Ebola virus. The study aimed to check safety and immune response, but it was terminated early, so results are limited.
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Jun 27, 2026 11:03 UTC
-
UK volunteers test new ebola vaccine combo in Early-Stage trial
Vaccine Stopped earlyThis early-stage trial tested the safety and immune response of two experimental Ebola vaccines in 38 healthy UK adults. Some volunteers received one vaccine, while others got a prime-boost combination. The vaccines use harmless viruses to train the immune system against Ebola wi…
Phase 1 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Jun 27, 2026 08:05 UTC